X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs DIVIS LABORATORIES - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH DIVIS LABORATORIES PANACEA BIOTECH/
DIVIS LABORATORIES
 
P/E (TTM) x 170.7 29.0 588.4% View Chart
P/BV x 3.8 5.0 75.5% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 PANACEA BIOTECH   DIVIS LABORATORIES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
DIVIS LABORATORIES
Mar-17
PANACEA BIOTECH/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1491,222 12.2%   
Low Rs82784 10.5%   
Sales per share (Unadj.) Rs84.1153.1 55.0%  
Earnings per share (Unadj.) Rs-18.339.9 -45.8%  
Cash flow per share (Unadj.) Rs-6.744.6 -15.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs83.7201.8 41.5%  
Shares outstanding (eoy) m61.25265.47 23.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.46.6 21.0%   
Avg P/E ratio x-6.325.1 -25.1%  
P/CF ratio (eoy) x-17.222.5 -76.7%  
Price / Book Value ratio x1.45.0 27.8%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m7,074266,266 2.7%   
No. of employees `0002.89.7 28.2%   
Total wages/salary Rs m1,4494,687 30.9%   
Avg. sales/employee Rs Th1,874.14,175.0 44.9%   
Avg. wages/employee Rs Th527.0481.5 109.4%   
Avg. net profit/employee Rs Th-407.71,089.3 -37.4%   
INCOME DATA
Net Sales Rs m5,15440,643 12.7%  
Other income Rs m100749 13.3%   
Total revenues Rs m5,25441,392 12.7%   
Gross profit Rs m-76614,460 -5.3%  
Depreciation Rs m7111,233 57.7%   
Interest Rs m1,50323 6,650.4%   
Profit before tax Rs m-2,88113,953 -20.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m173,349 0.5%   
Profit after tax Rs m-1,12110,604 -10.6%  
Gross profit margin %-14.935.6 -41.8%  
Effective tax rate %-0.624.0 -2.4%   
Net profit margin %-21.826.1 -83.4%  
BALANCE SHEET DATA
Current assets Rs m3,81040,105 9.5%   
Current liabilities Rs m8,3656,595 126.9%   
Net working cap to sales %-88.482.5 -107.2%  
Current ratio x0.56.1 7.5%  
Inventory Days Days156119 131.3%  
Debtors Days Days6781 83.3%  
Net fixed assets Rs m14,48019,995 72.4%   
Share capital Rs m61531 11.5%   
"Free" reserves Rs m90353,043 1.7%   
Net worth Rs m5,12753,574 9.6%   
Long term debt Rs m5,8320-   
Total assets Rs m19,43361,585 31.6%  
Interest coverage x-0.9618.4 -0.1%   
Debt to equity ratio x1.10-  
Sales to assets ratio x0.30.7 40.2%   
Return on assets %2.017.3 11.4%  
Return on equity %-21.919.8 -110.5%  
Return on capital %3.626.1 13.9%  
Exports to sales %24.50-   
Imports to sales %10.225.2 40.3%   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m52510,259 5.1%   
Fx inflow Rs m1,53935,384 4.4%   
Fx outflow Rs m94210,399 9.1%   
Net fx Rs m59724,985 2.4%   
CASH FLOW
From Operations Rs m59911,493 5.2%  
From Investments Rs m-438-11,372 3.9%  
From Financial Activity Rs m-303-93 325.0%  
Net Cashflow Rs m-14128 -497.5%  

Share Holding

Indian Promoters % 74.5 52.0 143.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.8 5.1%  
FIIs % 1.3 19.0 6.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.2 137.2%  
Shareholders   10,259 31,796 32.3%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Down; Tata Steel Top Loser(09:30 am)

Asian stocks rose in morning trade on Monday, after the US's S&P 500 extended its winning streak on Friday to six days. Markets in the Greater China region remain closed for the Lunar New Year holiday.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 19, 2018 11:43 AM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - NOVARTIS COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS